HK1168858A1 - Methods and compositions for treating neurodegenerative disorders and alzheimers disease and improving normal memory - Google Patents

Methods and compositions for treating neurodegenerative disorders and alzheimers disease and improving normal memory

Info

Publication number
HK1168858A1
HK1168858A1 HK12108377.2A HK12108377A HK1168858A1 HK 1168858 A1 HK1168858 A1 HK 1168858A1 HK 12108377 A HK12108377 A HK 12108377A HK 1168858 A1 HK1168858 A1 HK 1168858A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
neurodegenerative disorders
normal memory
treating neurodegenerative
Prior art date
Application number
HK12108377.2A
Other languages
English (en)
Chinese (zh)
Inventor
Nazneen Dewji
S Jonathan Singer
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1168858A1 publication Critical patent/HK1168858A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK12108377.2A 2009-05-12 2012-08-27 Methods and compositions for treating neurodegenerative disorders and alzheimers disease and improving normal memory HK1168858A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/464,850 US8129334B2 (en) 2006-03-31 2009-05-12 Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
PCT/US2010/034610 WO2010132609A2 (fr) 2009-05-12 2010-05-12 Procédés et compositions pour traiter des troubles neurodégénératifs et la maladie d'alzheimer et améliorer la mémoire normale

Publications (1)

Publication Number Publication Date
HK1168858A1 true HK1168858A1 (en) 2013-01-11

Family

ID=43085570

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12108377.2A HK1168858A1 (en) 2009-05-12 2012-08-27 Methods and compositions for treating neurodegenerative disorders and alzheimers disease and improving normal memory
HK16107844.5A HK1219744A1 (zh) 2009-05-12 2016-07-06 用於治療神經變性病症和阿爾茨海默病並改善正常記憶的方法和組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16107844.5A HK1219744A1 (zh) 2009-05-12 2016-07-06 用於治療神經變性病症和阿爾茨海默病並改善正常記憶的方法和組合物

Country Status (9)

Country Link
US (6) US8129334B2 (fr)
EP (1) EP2430038B1 (fr)
JP (3) JP5965313B2 (fr)
KR (1) KR101762454B1 (fr)
CN (3) CN105418750A (fr)
AU (1) AU2010249051B2 (fr)
CA (1) CA2760519C (fr)
HK (2) HK1168858A1 (fr)
WO (1) WO2010132609A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2005174A4 (fr) * 2006-03-31 2009-04-15 Univ California Procedes et compositions pour traiter des maladies neurodegeneratives, en particulier la maladie d'alzheimer, et ameliorer la memoire normale
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
WO2011156003A2 (fr) 2010-06-09 2011-12-15 New York University Oligomères peptoïdes et synthétiques, compositions pharmaceutiques et procédés d'utilisation de ceux-ci
US20120089291A1 (en) * 2010-10-12 2012-04-12 Halder Bibhrajit Autonomous machine control system
ES2530141B1 (es) * 2013-08-26 2016-01-15 Juan Carlos GALLAR RUIZ Péptido útil como diana farmacológica para el cribado de moléculas para el tratamiento y/o prevención de la enfermedad de Alzheimer, anticuerpo frente al mismo y uso del anticuerpo para el tratamiento y/o prevención de dicha enfermedad.
KR101956302B1 (ko) * 2016-11-30 2019-03-11 연세대학교 산학협력단 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물
ES2817910T3 (es) * 2017-08-04 2021-04-08 Alzheimur 2012 S L Uso de un anticuerpo antipresenilina para la prevención y/o tratamiento del cáncer
KR102075565B1 (ko) * 2017-10-24 2020-02-10 대한민국(환경부 국립생물자원관장) 마스토파란 mp-v1 항균 펩타이드와 프로테아제 억제제 또는 edta에서 선택된 하나 이상을 유효성분으로 포함하는 항균 조성물
CN108196408B (zh) * 2017-12-28 2021-03-23 Tcl华星光电技术有限公司 Coa基板的测试键以及使用其的测试方法
JP2021525245A (ja) * 2018-05-22 2021-09-24 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． アルツハイマー病のための遺伝子治療
JP7357369B2 (ja) 2018-07-23 2023-10-06 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
EP3870596A1 (fr) * 2018-10-22 2021-09-01 University of Copenhagen Inhibiteurs exprimés de manière virale de domaines pdz, tels que pick1 et leurs utilisations
WO2020146236A1 (fr) * 2019-01-07 2020-07-16 Cenna Biosciences Inc. Nouveaux peptides et utilisations associées
IL293285A (en) * 2019-11-29 2022-07-01 Paros Bio Inc Gene therapy for neurodegenerative disorders
CN113402587B (zh) * 2021-07-08 2022-05-10 荣成泰祥食品股份有限公司 一种八肽及其在制备改善记忆的药品中的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
EP0276846A3 (fr) 1987-01-29 1989-07-26 Zymogenetics, Inc. Dérivés du facteur stimulant des colonies
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
CA2089661C (fr) 1990-08-29 2007-04-03 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1993021259A1 (fr) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Macromolecules dendritiques et leur procede de production
ATE350386T1 (de) 1992-11-13 2007-01-15 Immunex Corp Elk ligand, ein cytokin
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
CN1188508A (zh) * 1995-04-28 1998-07-22 Hsc研究和发展合伙人有限公司 与早老性痴呆病有关的基因序列和蛋白及其用途
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5824519A (en) 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
US5679523A (en) 1995-11-16 1997-10-21 The Board Of Trustees Of The Leland Stanford Junior University Method for concurrent disruption of expression of multiple alleles of mammalian genes
US5985581A (en) * 1996-07-25 1999-11-16 The Mclean Hospital Corporation Use of presenilin-1 for diagnosis of alzheimers disease
CA2267139A1 (fr) 1996-10-08 1998-04-16 Ton Logtenberg Procedes et systemes permettant de selectionner des peptides et des proteines qui possedent une affinite specifique envers une cible
EP0977776A2 (fr) 1997-04-24 2000-02-09 The General Hospital Corporation Fragment c-terminal purifie de preseniline 2, de 20 kda, et procedes de selection de composes qui inhibent la proteolyse de la preseniline 2
EP0981602A4 (fr) 1997-05-14 2003-01-02 Merck & Co Inc Animal transgenique exprimant une proteine preseniline 1 mutante non native de type sauvage de la maladie d'alzheimer familiale dans un contexte depourvu de preseniline 1 native
US6284944B1 (en) 1997-08-29 2001-09-04 Cephalon, Inc, Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring
EP1025121B1 (fr) * 1997-10-24 2011-08-24 Aventis Pharma S.A. Peptides capables d'inhiber l'interaction entre les presenilines et le peptide beta-amyloide ou son precurseur
US6653088B1 (en) 1997-10-24 2003-11-25 Aventis Pharma S.A. Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
WO2000004150A1 (fr) 1998-07-16 2000-01-27 Incyte Pharmaceuticals, Inc. Proteine humaine associee a la preseniline
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6812337B1 (en) 1999-04-01 2004-11-02 The Governing Council Of The University Of Toronto Presenilin associated membrane protein and uses thereof
US6979537B2 (en) 2000-01-10 2005-12-27 Scios, Inc. Methods for identifying inhibitors of neuronal degeneration
AU2001237412A1 (en) 2000-02-25 2001-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Presenilin deficient multipotent cell lines and screening methods for intramembrane regulated proteolytic activities using these lines
GB0005895D0 (en) 2000-03-10 2000-05-03 Glaxo Group Ltd Novel assay
GB0005894D0 (en) 2000-03-10 2000-05-03 Glaxo Group Ltd Assay
JP2003533187A (ja) 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド 治療薬としてのＦｃドメインを含む修飾ペプチド
AU2001268328A1 (en) 2000-06-12 2001-12-24 University Of Maryland Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
JP2003018991A (ja) 2001-06-27 2003-01-21 Japan Science & Technology Corp プレセニリン−２遺伝子エキソン５欠損型スプライシング異常の生成に関与する核酸
US20030175278A1 (en) 2001-11-13 2003-09-18 Monteiro Mervyn J. Ubiquilin, a presenilin interactor and methods of using same
CA2490278A1 (fr) 2002-06-26 2004-01-22 Cellzome Ag Constituants du complexe de preseniline
US7271313B2 (en) 2003-04-09 2007-09-18 The Brigham And Women's Hospital, Inc. Presenilin-deficient mouse model of age-dependent neurodegeneration and cognitive loss
CN1991364A (zh) 2005-12-26 2007-07-04 中国科学院上海生命科学研究院 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂
WO2007092861A2 (fr) 2006-02-06 2007-08-16 Elan Pharmaceuticals, Inc. Inhibition preferentielle de la preseniline-i
US8129334B2 (en) * 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
EP2005174A4 (fr) 2006-03-31 2009-04-15 Univ California Procedes et compositions pour traiter des maladies neurodegeneratives, en particulier la maladie d'alzheimer, et ameliorer la memoire normale
CN101454671A (zh) * 2006-03-31 2009-06-10 加利福尼亚大学董事会 用于治疗神经变性疾病和阿尔茨海默病以及改善正常记忆的方法和组合物

Also Published As

Publication number Publication date
US8129334B2 (en) 2012-03-06
JP2012526557A (ja) 2012-11-01
KR101762454B1 (ko) 2017-07-27
AU2010249051A1 (en) 2011-12-01
CN110590906A (zh) 2019-12-20
EP2430038A2 (fr) 2012-03-21
EP2430038B1 (fr) 2015-04-22
US20090305946A1 (en) 2009-12-10
US20170073384A1 (en) 2017-03-16
AU2010249051B2 (en) 2014-06-12
JP2016117729A (ja) 2016-06-30
US20150299279A1 (en) 2015-10-22
KR20120024741A (ko) 2012-03-14
CA2760519A1 (fr) 2010-11-18
JP6329122B2 (ja) 2018-05-23
JP2018138040A (ja) 2018-09-06
HK1219744A1 (zh) 2017-04-13
US10774121B2 (en) 2020-09-15
WO2010132609A2 (fr) 2010-11-18
WO2010132609A3 (fr) 2011-04-07
US8951794B2 (en) 2015-02-10
US10221223B2 (en) 2019-03-05
JP5965313B2 (ja) 2016-08-03
US20120214235A1 (en) 2012-08-23
CN105418750A (zh) 2016-03-23
CA2760519C (fr) 2020-10-27
EP2430038A4 (fr) 2013-02-06
CN103282374A (zh) 2013-09-04
US9512191B2 (en) 2016-12-06
US20200017562A1 (en) 2020-01-16
CN103282374B (zh) 2016-02-03
US20210163557A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
HK1219744A1 (zh) 用於治療神經變性病症和阿爾茨海默病並改善正常記憶的方法和組合物
IL262668A (en) Preparations for the treatment of Gaucher disease
IL217703A0 (en) Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
HK1174064A1 (zh) 用於細胞增殖相關的疾病的方法和組合物
EP2170309A4 (fr) Procédés et compositions pour le traitement de troubles
EP2406389A4 (fr) Procédés et compositions pour des troubles liés à la prolifération cellulaire
IL209032A0 (en) Compositions and methods for treating digestive disorders
EP2461819A4 (fr) Procédés et compositions de traitement de troubles de répétition tri-nucléotidique
HK1217100A1 (zh) 檢測和治療阿爾茨海默病和相關疾病的化合物和組合物
IL208981B (en) Combined preparations for the treatment of Alzheimer's disease and related disorders with zonisamide
HK1170150A1 (en) New compositions for treating cmt and related disorders
IL209216A (en) Preparations for the prevention and treatment of neurodegenerative diseases
EP2691102A4 (fr) Composition d'herbes pour le traitement de maladies neurologiques et l'amélioration des troubles de la mémoire
EP2309858A4 (fr) Compositions et procédés de traitement de troubles inflammatoires
ZA201203002B (en) Compositions and methods for treating inflammatory disorders
EP2550361A4 (fr) Compositions et procédés pour traiter des troubles neurologiques
EP2486402A4 (fr) Compositions et méthodes de diagnostic de maladies et de troubles associés au génome
EP2515925A4 (fr) Compositions et méthodes pour prévenir et traiter les maladies et les troubles de santé induits par l'environnement
EP2491019A4 (fr) Méthodes et compositions pour les troubles de panique
HK1183807A1 (zh) 用於治療神經變性疾病或神經病理性病症的組合物
EP2219650A4 (fr) Compositions et procédés permettant de traiter des troubles fibroprolifératifs
EP2237777A4 (fr) Compositions et procédés pour traiter des maladies neurodégénératives
IL207906A0 (en) Treatment for ocular-related disorders
EP2501672A4 (fr) Compositions et méthodes de traitement de troubles hyperprolifératifs
EP2278982A4 (fr) Compositions et procédés de traitement de maladies neurodégénératives